Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a clinical-stage biopharmaceutical company focused on oral antiviral therapeutics for serious viral diseases, and its news flow reflects this development-driven profile. Company announcements frequently center on progress in its hepatitis C virus (HCV) program, where Atea is advancing a fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, and ruzasvir, an NS5A inhibitor.
News items include updates on the global Phase 3 HCV program, such as enrollment milestones in the C-BEYOND and C-FORWARD trials, expectations for topline results, and details of trial design, endpoints and patient populations. Atea also reports new clinical and nonclinical data, including Phase 2 efficacy results, resistance analyses, pharmacokinetic findings and multiscale modeling that explore the regimen’s antiviral activity, barrier to resistance, relative bioavailability and dosing flexibility.
Investors and observers can also find press releases about Atea’s participation in major medical and investor conferences, including presentations at The Liver Meeting of the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Congress, as well as appearances at healthcare investment conferences. These communications often highlight new data sets, key opinion leader events and discussions of the HCV commercial landscape.
In addition, Atea’s news coverage includes pipeline expansion updates, notably the development of nucleotide analog candidates AT-587 and AT-2490 for hepatitis E virus (HEV), along with background on the unmet medical need in HEV and the company’s preclinical findings. Financial results releases and business updates, furnished in connection with quarterly reports, provide further context on research and development spending, cash resources and strategic priorities. For those tracking AVIR, this news page offers a centralized view of clinical progress, scientific presentations, pipeline evolution and corporate developments.
Atea Pharmaceuticals (AVIR) announces strategic priorities for 2025, focusing on its global Phase 3 program for HCV treatment. The company plans to initiate trials for its bemnifosbuvir and ruzasvir regimen in Q1 2025, targeting a $3 billion global HCV market.
The company reports $454.7 million in cash and equivalents as of December 31, 2024, with runway extending into 2028. The Phase 3 program will include two open-label trials, each enrolling up to 800 treatment-naïve HCV patients. The trials will evaluate 8-week treatment for non-cirrhotic patients and 12-week treatment for cirrhotic patients, compared to sofosbuvir/velpatasvir.
Market research indicates strong healthcare provider interest in prescribing the regimen and positive payor receptiveness. The treatment aims to address the significant global HCV burden, affecting an estimated 50 million people worldwide with approximately one million new infections annually.
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. Jean-Pierre Sommadossi, PhD, the company's CEO and Founder, will deliver a business update presentation on Wednesday, January 15, 2025 at 5:15 p.m. PT in San Francisco.
The presentation will be accessible via live webcast on the company's investor relations website, with the recording remaining available for at least 90 days following the event.
Atea Pharmaceuticals (NASDAQ: AVIR) is facing pressure from a Concerned Shareholder Group owning approximately 3% of outstanding shares. The group criticizes the company's performance and governance, particularly focusing on Lead Independent Director Franklin M. Berger's recent sale of 359,606 shares at $2.84 per share, near all-time lows and below net cash value.
The shareholders highlight that the Board previously rejected Tang Capital's bid of $5.75 per share plus rights to 80% of net proceeds from drug programs in May 2023. They believe the company can deliver $4.75 per share in cash to shareholders, representing a 50% premium over current price. The group demands Berger's immediate resignation and calls for appointment of a new, shareholder-oriented Lead Independent Director to oversee the ongoing strategic review process with Evercore.
Atea Pharmaceuticals (AVIR) has announced the engagement of Evercore, a global independent investment bank, to explore strategic opportunities aimed at enhancing shareholder value. The primary focus is on identifying potential strategic partnerships for their Phase 3-ready hepatitis C virus (HCV) treatment program. The company has not established a timeline for completing this review process and has not made any definitive decisions. Atea states it will not provide further updates until either the Board of Directors approves a specific course of action, the review concludes, or disclosure becomes necessary. The company emphasizes that there is no guarantee this process will lead to any specific transaction or outcome.
Atea Pharmaceuticals (NASDAQ: AVIR) announced positive Phase 2 study results for its HCV treatment combining bemnifosbuvir and ruzasvir. The study met its primary endpoints with a 98% sustained virologic response rate at 12 weeks post-treatment in treatment-adherent patients after an eight-week regimen.
The treatment showed 95% efficacy in the overall evaluable population, including non-adherent patients. The regimen was generally safe with no drug-related serious adverse events. Non-cirrhotic patients achieved a 99% success rate, while cirrhotic patients showed 88% efficacy.
The company plans to initiate a Phase 3 program in early 2025, following an FDA meeting. The upcoming phase will feature a fixed-dose combination tablet, reducing daily pill count from four to two tablets.
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has announced its participation in the 7th Annual Evercore HealthCONx Conference. Jean-Pierre Sommadossi, CEO and Founder, along with the management team, will deliver a business update and participate in a fireside chat on December 4, 2024, at 9:35 a.m. ET. The presentation will be accessible via live webcast on the company's website and will remain available for at least 90 days after the event.
Atea Pharmaceuticals (AVIR) presented three posters at AASLD's The Liver Meeting 2024 supporting the combination of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) treatment. The Phase 2 lead-in cohort showed a 97% SVR12 success rate with an 8-week treatment course. Key findings include: the drug combination effectively blocks viral replication and assembly, bemnifosbuvir demonstrates no clinically relevant effects on cardiac function, and shows a high barrier to resistance. The company plans to report full Phase 2 results in early December and initiate Phase 3 development in early 2025.
Atea Pharmaceuticals (AVIR) reported Q3 2024 financial results and provided updates on its HCV program. The company expects topline SVR12 results from its global Phase 2 Hepatitis C study (N=275) in December 2024. Earlier data showed 97% SVR12 rate in efficacy evaluable patients. The company ended Q3 with $482.8 million in cash and equivalents. Research and development expenses were $26.2 million, down from $28.2 million year-over-year. The company reported a net loss of $31.2 million for Q3 2024. Notably, Atea announced it will not pursue COVID-19 treatment development after its Phase 3 SUNRISE-3 trial failed to meet its primary endpoint.
Atea Pharmaceuticals (Nasdaq: AVIR) announced it will host a conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to discuss third quarter 2024 financial results and provide a business update. The event will be accessible via telephone registration and webcast through the company's investor relations website. An archive of the webcast will be available for at least 90 days following the event.
Atea Pharmaceuticals (NASDAQ: AVIR) announced three upcoming poster presentations at AASLD's The Liver Meeting 2024 in San Diego, showcasing new data on the combination of bemnifosbuvir and ruzasvir for Hepatitis C Virus (HCV) treatment. The combination, currently in Phase 2 development, pairs a nucleotide analog polymerase inhibitor with an NS5A inhibitor.
The presentations, scheduled for November 15, will cover multiscale modeling of Phase 2 study results, cardiac repolarization effects, and resistance barrier studies. The company aims to address unmet needs in HCV treatment, particularly for patients with substance abuse disorders and comorbidities, and plans to advance to Phase 3 development following Phase 2 results later this year.